Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07600736
PHASE2

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric Participants With KCNT1-related Epilepsy

Sponsor: Actio Biosciences, Inc.

View on ClinicalTrials.gov

Summary

This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy

Official title: A Phase 1b/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 Administered to Pediatric Participants With KCNT1-Related Epilepsy

Key Details

Gender

All

Age Range

1 Month - 21 Years

Study Type

INTERVENTIONAL

Enrollment

45

Start Date

2026-05-18

Completion Date

2028-01

Last Updated

2026-06-10

Healthy Volunteers

No

Interventions

DRUG

ABS-1230

Once daily

DRUG

Placebo

Once daily

Locations (1)

Northeast Regional Epilepsy Group

Hackensack, New Jersey, United States